Home Alzheimer’s Disease Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?

Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?

The Case

A female patient, age 11 years, presented with a firm, palpable mass in the left lower quadrant of the abdomen. Upon ultrasound imaging, the 3.5 cm × 5 cm lesion was assessed as a benign cyst and a laparoscopic resection of the mass was performed. The initial pathological evaluation reported a diagnosis of fibromyxoid sarcoma. However, after an additional immunohistochemical examination, the diagnosis was changed to grade III synovial sarcoma (CD45–, Bcl+, Desmin–, WT1–, SMA–, Ki65-15%) (Figure 1). Detection of t(X;18) (p11.2; q11.2) translocation was not yet available in Armenia at that time. The pathology report did not include the state of margins. CT and bone scans revealed no metastatic disease at the time.

What would be the best choice for further management of this patient?

A. Observation

B. Radiotherapy

C. Resurgery, with further treatment including radiotherapy…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments